402 related articles for article (PubMed ID: 34322383)
1. Early and Next-Generation KIT/PDGFRA Kinase Inhibitors and the Future of Treatment for Advanced Gastrointestinal Stromal Tumor.
Bauer S; George S; von Mehren M; Heinrich MC
Front Oncol; 2021; 11():672500. PubMed ID: 34322383
[TBL] [Abstract][Full Text] [Related]
2. Ripretinib for the treatment of advanced gastrointestinal stromal tumor.
Zalcberg JR
Therap Adv Gastroenterol; 2021; 14():17562848211008177. PubMed ID: 33948116
[TBL] [Abstract][Full Text] [Related]
3. Circulating tumor DNA analysis of the phase III VOYAGER trial: KIT mutational landscape and outcomes in patients with advanced gastrointestinal stromal tumor treated with avapritinib or regorafenib.
Serrano C; Bauer S; Gómez-Peregrina D; Kang YK; Jones RL; Rutkowski P; Mir O; Heinrich MC; Tap WD; Newberry K; Grassian A; Shi H; Bialick S; Schöffski P; Pantaleo MA; von Mehren M; Trent JC; George S
Ann Oncol; 2023 Jul; 34(7):615-625. PubMed ID: 37105265
[TBL] [Abstract][Full Text] [Related]
4. Gastrointestinal Stromal Tumors: What Is the Best Sequence of TKIs?
Senchak J; Ahr K; von Mehren M
Curr Treat Options Oncol; 2022 May; 23(5):749-761. PubMed ID: 35349049
[TBL] [Abstract][Full Text] [Related]
5. Emerging drugs for the treatment of gastrointestinal stromal tumors.
Pilco-Janeta DF; García-Valverde A; Gomez-Peregrina D; Serrano C
Expert Opin Emerg Drugs; 2021 Mar; 26(1):53-62. PubMed ID: 33645383
[TBL] [Abstract][Full Text] [Related]
6. Ripretinib and MEK Inhibitors Synergize to Induce Apoptosis in Preclinical Models of GIST and Systemic Mastocytosis.
Gupta A; Singh J; García-Valverde A; Serrano C; Flynn DL; Smith BD
Mol Cancer Ther; 2021 Jul; 20(7):1234-1245. PubMed ID: 33947686
[TBL] [Abstract][Full Text] [Related]
7. Clinical Activity of Ripretinib in Patients with Advanced Gastrointestinal Stromal Tumor Harboring Heterogeneous
Bauer S; Heinrich MC; George S; Zalcberg JR; Serrano C; Gelderblom H; Jones RL; Attia S; D'Amato G; Chi P; Reichardt P; Meade J; Su Y; Ruiz-Soto R; Blay JY; von Mehren M; Schöffski P
Clin Cancer Res; 2021 Dec; 27(23):6333-6342. PubMed ID: 34503977
[TBL] [Abstract][Full Text] [Related]
8. KIT/PDGFRA inhibitors for the treatment of gastrointestinal stromal tumors: getting to the gist of the problem.
Cicala CM; Olivares-Rivas I; Aguirre-Carrillo JA; Serrano C
Expert Opin Investig Drugs; 2024 Mar; 33(3):159-170. PubMed ID: 38344849
[TBL] [Abstract][Full Text] [Related]
9. [Gastrointestinal stromal tumors (GIST)].
Jaros D; Bozic B; Sebesta C
Wien Med Wochenschr; 2023 Jun; 173(9-10):201-205. PubMed ID: 36155864
[TBL] [Abstract][Full Text] [Related]
10. Avapritinib in Patients With Advanced Gastrointestinal Stromal Tumors Following at Least Three Prior Lines of Therapy.
George S; Jones RL; Bauer S; Kang YK; Schöffski P; Eskens F; Mir O; Cassier PA; Serrano C; Tap WD; Trent J; Rutkowski P; Patel S; Chawla SP; Meiri E; Gordon M; Zhou T; Roche M; Heinrich MC; von Mehren M
Oncologist; 2021 Apr; 26(4):e639-e649. PubMed ID: 33453089
[TBL] [Abstract][Full Text] [Related]
11. Ripretinib in gastrointestinal stromal tumor: the long-awaited step forward.
Lostes-Bardaji MJ; García-Illescas D; Valverde C; Serrano C
Ther Adv Med Oncol; 2021; 13():1758835920986498. PubMed ID: 33473249
[TBL] [Abstract][Full Text] [Related]
12. [The importance of mutational status in prognosis and therapy of GIST].
Comandone A; Boglione A
Recenti Prog Med; 2015 Jan; 106(1):17-22. PubMed ID: 25621775
[TBL] [Abstract][Full Text] [Related]
13. Robust Activity of Avapritinib, Potent and Highly Selective Inhibitor of Mutated KIT, in Patient-derived Xenograft Models of Gastrointestinal Stromal Tumors.
Gebreyohannes YK; Wozniak A; Zhai ME; Wellens J; Cornillie J; Vanleeuw U; Evans E; Gardino AK; Lengauer C; Debiec-Rychter M; Sciot R; Schöffski P
Clin Cancer Res; 2019 Jan; 25(2):609-618. PubMed ID: 30274985
[TBL] [Abstract][Full Text] [Related]
14. Clinical efficacy comparison of avapritinib with other tyrosine kinase inhibitors in gastrointestinal stromal tumors with PDGFRA D842V mutation: a retrospective analysis of clinical trial and real-world data.
von Mehren M; Heinrich MC; Shi H; Iannazzo S; Mankoski R; Dimitrijević S; Hoehn G; Chiroli S; George S
BMC Cancer; 2021 Mar; 21(1):291. PubMed ID: 33740926
[TBL] [Abstract][Full Text] [Related]
15. The multifaceted landscape behind imatinib resistance in gastrointestinal stromal tumors (GISTs): A lesson from ripretinib.
Di Vito A; Ravegnini G; Gorini F; Aasen T; Serrano C; Benuzzi E; Coschina E; Monesmith S; Morroni F; Angelini S; Hrelia P
Pharmacol Ther; 2023 Aug; 248():108475. PubMed ID: 37302758
[TBL] [Abstract][Full Text] [Related]
16. Progression of the tumor in a patient with a gastrointestinal stromal tumor with the
An Z; Tan M; Xia Y; Li Y; Fan L; Zhao Q; Zhang Z; Tan B; Liu Y; Ma Z; Wang D; Zhao X
J Gastrointest Oncol; 2022 Oct; 13(5):2620-2625. PubMed ID: 36388657
[TBL] [Abstract][Full Text] [Related]
17. Systemic therapy of advanced/metastatic gastrointestinal stromal tumors: an update on progress beyond imatinib, sunitinib, and regorafenib.
Mohammadi M; Gelderblom H
Expert Opin Investig Drugs; 2021 Feb; 30(2):143-152. PubMed ID: 33252274
[No Abstract] [Full Text] [Related]
18. Gastrointestinal stromal tumor: a review of current and emerging therapies.
Al-Share B; Alloghbi A; Al Hallak MN; Uddin H; Azmi A; Mohammad RM; Kim SH; Shields AF; Philip PA
Cancer Metastasis Rev; 2021 Jun; 40(2):625-641. PubMed ID: 33876372
[TBL] [Abstract][Full Text] [Related]
19. [Advanced GIST: Which treatments in 2022?].
Mas L; Bachet JB
Bull Cancer; 2022 Oct; 109(10):1082-1087. PubMed ID: 35934543
[TBL] [Abstract][Full Text] [Related]
20. Combination of Type I and II tyrosine kinase inhibitors-avapritinib and sunitinib-in refractory gastrointestinal stromal tumor after failure to multi-line therapy: a case report.
Guo X; Huang S; Shi Y; Guan Z; Chen S; Feng Y; Xia Y; Zhang X
Ann Transl Med; 2022 Sep; 10(18):1026. PubMed ID: 36267752
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]